Shots:
- The US FDA has granted FTD to HMI-115 for the treatment of mod. to sev. pain associated with endometriosis
- Designation was based on the global P-II dose-finding study assessing HMI-115 vs PBO for 12wks. in 108 females with surgically diagnosed endometriosis across the US, Poland & China, showing significant improvement
- Trial showed that HMI-115 (240mg, Q2W) decreased mean dysmenorrhea pain score by 42% & non-menstrual chronic pelvic pain score by 52%, with no peri-menopausal symptoms & no meaningful changes in menstrual cycles, bone density, or sex hormone levels; data published in The Lancet Obstetrics, Gynaecology & Women’s Health
Ref: PRnewswire | Image: Hope Medicine |Press Release
Related News:
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
